Literature DB >> 19657349

Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success.

R Shabsigh1, C Donatucci, R Costabile, M A Perelman, P Burns, H Zeigler, D G Wong.   

Abstract

The reliability of response to treatment is an important component of erectile dysfunction (ED) treatment. This study examined the reliability of tadalafil once daily (that is, successful attempts/total attempts) following initial successful intercourse. Data pooled from two randomized, double-blind, placebo-controlled trials of men with ED who received tadalafil 2.5 mg (N=96), tadalafil 5 mg (N=206) or placebo (N=148) once daily were analyzed to determine the first-attempt success rate and subsequent reliability of response. The first-attempt success rate (Sexual Encounter Profile question 3 (SEP3)) was significantly higher among men taking tadalafil 2.5 mg (45.7%) and 5 mg (55.2%) compared to placebo (28.5%; P<0.05 and P<0.001, respectively). Furthermore, following initial success, men taking tadalafil 5 mg had a significantly greater proportion of successful intercourse (SEP3) on subsequent attempts (85.9%, P<0.001) compared to men taking placebo (70.2%). Overall, men with ED taking tadalafil once daily experienced a high rate of reliability of efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657349     DOI: 10.1038/ijir.2009.29

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  3 in total

1.  Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.

Authors:  H Choi; J-H Kim; J-S Shim; J Y Park; S H Kang; D G Moon; J Cheon; J G Lee; J J Kim; J-H Bae
Journal:  Int J Impot Res       Date:  2014-07-03       Impact factor: 2.896

Review 2.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Authors:  Samuel L Washington; Alan W Shindel
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

3.  Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

Authors:  Hyun Hwan Sung; Sung Won Lee
Journal:  Korean J Urol       Date:  2012-06-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.